Latest Clinical Research News

Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.

dorsaVi has commenced development of Sensor V6.5, a firmware upgrade that embeds intelligence directly within its wearable sensors, reducing latency and paving the way for future neuromorphic computing integration.

Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.